Veroshpilactone

1 tablet contains:

Active substance:

spironolactone 50 mg.

Spironolactone, being an aldosterone antagonist, competitively binds to aldosterone receptors in the distal renal tubules.

Aldosterone acts as a potassium-sparing diuretic by increasing the amount of sodium and water excreted from the body while delaying the release of potassium and magnesium.

The diuretic effect usually develops on the 2-5th day of treatment and persists for 2-3 days after discontinuation of the drug.

• Edema syndrome in chronic heart failure, liver cirrhosis (especially with the simultaneous presence of hypokalemia and hyperaldosteronism), nephrotic syndrome; 
• essential hypertension in adults; 
• ascites; 
• diagnosis and treatment of primary hyperaldosteronism (Conn's syndrome); 
• prevention of hypokalemia in the treatment of saluretics and in patients receiving cardiac glycosides, myasthenia gravis (adjuvant).

Hypersensitivity, Addison's disease, acute or rapidly progressive renal failure, chronic renal failure with a significant decrease in excretory function (Cl creatinine less than 10 ml / min), anuria, hyperkalemia, hyponatremia, hypercalcemia.

With caution:  Decreased renal excretory function, impaired liver function (increased sensitivity to changes in electrolyte balance), diabetes mellitus (especially diabetic nephropathy), predisposition to metabolic acidosis (with acidosis, the hyperkalemic effect of spironolactone increases, spironolactone may contribute to the development of acidosis), menstrual irregularities and / or enlargement of the mammary glands, AV blockade (possibly increased due to the development of hyperkalemia).

From the nervous system and sensory organs:  dizziness, drowsiness, lethargy, lethargy, headache, ataxia, confusion.

From the digestive tract:  nausea, vomiting, diarrhea, spasms, intestinal colic, gastritis, ulceration and bleeding in the gastrointestinal tract, liver dysfunction.

From the genitourinary system:  gynecomastia (usually reversible, in rare cases it can persist after drug withdrawal), pain in the mammary glands, erectile dysfunction in men, decreased potency in men, menstrual irregularities or amenorrhea, metrorrhagia in menopause, hirsutism, voice change among women.

On the part of the skin:  maculopapular or erythematous skin rashes, alopecia, hypertrichosis, pruritus, urticaria.

Others:  cramps of the calf muscles, benign neoplasms of the mammary gland, chest pain, leukopenia (including agranulocytosis), thrombocytopenia, electrolyte imbalance, hyperkalemia, increased blood urea nitrogen, creatinine, osteomalacia, drug fever.

The tablets are taken orally after meals.

Adults can take the daily dose in one or more doses.

Edema against the background of chronic heart failure: the  initial dose is 25 mg / day, the maximum dose is 100 mg / day. The maintenance dose is determined individually.

Edema against the background of liver cirrhosis:  100-400 mg / day (depending on the ratio of potassium and sodium). The maintenance dose is determined individually.

Peripheral edema against the background of nephrotic syndrome: the  daily dose is 100-200 mg / day.

Essential hypertension  in adults: 50-100 mg / day. If necessary, the daily dose can be gradually increased over two weeks to 200 mg / day. The duration of treatment is at least 2 weeks.

Children:  usually prescribed at the rate of 3 mg / kg of body weight per day. The dose should be selected based on their response and drug tolerance. The frequency of admission is usually 1-2 times a day.

Diagnosis and treatment of primary hyperaldosteronism:  can be used for initial diagnosis, as an indirect indicator of primary hyperaldosteronism in patients on a normal diet. Long test:  adults - 400 mg / day for 3-4 weeks. Elimination of hypokalemia and arterial hypertension indirectly testifies in favor of the diagnosis of primary hyperaldosteronism. Short test: the daily dose for adults is 400 mg for 4 days. If, during the period of taking spironolactone, the concentration of potassium ions in the blood serum rises, but falls when spironolactone is discontinued, primary hyperaldosteronism should be considered as a possible diagnosis. After the diagnosis of hyperaldosteronism is made using more informative diagnostic tests, spironolactone can be taken in preparation for surgery at a dose of 100 to 400 mg / day.

In patients who are not subject to surgery, Veroshpilactone can be used as a long-term maintenance therapy in the lowest effective doses that are set individually for the patient.

Prevention of hypokalemia during treatment with saluretics:  25-100 mg / day.

Missed dose:  Take the missed dose as soon as possible. Do not take it if there is no time before the next dose. Do not take a double dose.

Symptoms:  nausea, vomiting, drowsiness, confusion, skin rash, diarrhea.

Electrolyte imbalance and dehydration are possible.

Treatment:  taking Veroshpilactone should be stopped immediately, induce vomiting and wash out the stomach.

There is no specific antidote.

Symptomatic treatment of dehydration, electrolyte imbalance and arterial hypotension should be carried out.

Elimination of hyperkalemia is achieved by rapid administration of glucose (20-50% solutions) and insulin at the rate of 0.25-0.5 U of insulin per 1 g of glucose.

Potassium-excreting diuretics and ion exchange resins are used.